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Strengths and limitations of this study
 ► There is no evidence on the use of HIVself- testing to 
improve linkage to effective HIV prevention such as 
pre- exposure prevention.
 ► There is limited evidence on the strength and lim-
itations of different peer- to- peer approaches to im-
prove uptake of HIV testing and linkage to care and 
prevention.
 ► Strengths include the use of a cluster randomised 
controlled trial (cRCT) with rigorous measurement 
of the outcome linkage to care or prevention by 
arm, combined with process evaluation and cost- 
effectiveness studies.
 ► By embedding this cRCT within a longitudinal demo-
graphic surveillance setting, we are able to measure 
the population reach of the intervention.
 ► Limitations include a small risk of contamination 
across clusters and potential for coercive test or in-
timate partner violence.
AbStrACt
Introduction A cluster randomised controlled trial (cRCT) 
to determine whether HIV self- testing (HIVST) delivered by 
peers either directly or through incentivised peer- networks, 
could increase the uptake of antiretroviral therapy and 
pre- exposure prophylaxis (PrEP) among young women (18 
to 24 years) is being undertaken in an HIV hyperendemic 
area in KwaZulu- Natal, South Africa.
Methods and analysis A three- arm cRCT started mid- 
March 2019, in 24 areas in rural KwaZulu- Natal. Twenty- 
four pairs of peer navigators working with ~12 000 young 
people aged 18 to 30 years over a period of 6 months 
were randomised to: (1) incentivised- peer- networks: peer- 
navigators recruited participants ‘seeds’ to distribute up to 
five HIVST packs and HIV prevention information to peers 
within their social networks. Seeds receive an incentive 
(20 Rand = US$1.5) for each respondent who contacts a 
peer- navigator for additional HIVST packs to distribute; 
(2) peer- navigator- distribution: peer- navigators distribute 
HIVST packs and information directly to young people; 
(3) standard of care: peer- navigators distribute referral 
slips and information. All arms promote sexual health 
information and provide barcoded clinic referral slips 
to facilitate linkage to HIV testing, prevention and care 
services. The primary outcome is the difference in linkage 
rate between arms, defined as the number of women (18 
to 24 years) per peer- navigators month of outreach work (/
pnm) who linked to clinic- based PrEP eligibility screening 
or started antiretroviral, based on HIV- status, within 90 
days of receiving the clinic referral slip.
Ethics and dissemination This study was approved by 
the Institutional Review Boards at the WHO, Switzerland 
(Protocol ID: StAr Crt, South Africa), London School 
of Hygiene and Tropical Medicine, UK (reference: 15 
990–1), University of KwaZulu- Natal (bFC311/18) and 
the KwaZulu- Natal Department of Health (reference: 
KZ_201901_012), South Africa. The findings of this trial 
will be disseminated at local, regional and international 
meetings and through peer- reviewed publications.
trial registration number NCT03751826. Protocol date: 
17 January 2019.
IntroDuCtIon
South Africa has the largest burden of 
HIV globally with 14% national prevalence 
rate and an estimated 7.9 million people 
living with HIV in 2017.1 The province of 
KwaZulu- Natal (KZN) is mostly affected 
by the epidemic with an 18.1% prevalence 
rate in 2017,1 while our research setting in 
uMkhanyakude district has an estimated 
30% in the general population.2 Of the 
new 88 000 HIV infections recorded among 
young people aged 15 to 24 years in 2017, 66 
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000 were among females.1 Similarly, there is high HIV 
incidence rate in adolescent girls and young women 
(AGYW) with an estimated 5% per annum in aged 15 
to 19 years and 8% per annum in aged 20 to 24 years, 
respectively, in our research setting in Hlabisa subdis-
trict.3 This high incidence persists despite an increasing 
range of effective HIV prevention and treatment inter-
ventions, including condoms, antiretroviral (ART) 
based prevention for example, pre- exposure prophy-
laxis (PrEP), universal test and treat4 5 and voluntary 
medical male circumcision (VMMC).
Evidence from South Africa and other countries in 
sub- Saharan Africa shows that this is partly due to the 
fact that many young people living with HIV are undi-
agnosed and therefore not linked to care.6 7 Similarly, a 
recent treatment- as- prevention trial conducted in this 
area failed to show an impact on incidence in part due 
to the challenge of testing and linking young women.8 
Patient level fears (eg, stigma, labelling and discrimina-
tion) and facility level barriers (eg, distance, waiting times 
and provider attitudes) continue to be barriers to young 
people not seeking HIV care services (HIV testing and 
uptake and adherence to antiretroviral therapy for treat-
ment) in health facilities.9–11 There is an urgent need to 
increase the proportion of those (particularly AGYW) 
who know their HIV status and take up effective HIV 
treatment as well as prevention — including ART based 
care and prevention.
To increase global testing rates and early access to 
treatment or PrEP, HIV self- testing (HIVST) — a simple 
saliva or blood- based self- test similar to a pregnancy 
test — has been identified as a potential method given 
its privacy and convenience.12–16 Studies from different 
countries including South Africa have shown high 
acceptability and uptake of HIVST particularly among 
first time testers and young people.13 14 16–19 Also, a 
growing number of studies have shown that rapid oral 
fluid testing was preferred to blood- based testing.20–22 
The OraQuick In- home HIV test (OraSure Technolo-
gies, Inc, Bethlehem, Pennsylvania, manufactured in 
Thailand) was recently pre- qualified by the WHO for 
international procurement.23 Field based use confirmed 
the high accuracy of HIVST, although with some vari-
ability across different educational levels.14 18 24 HIVST 
(OraQuick) product is currently available in South 
Africa and has been endorsed by the National Depart-
ment of Health (NDoH) in those aged 18 and above, 
with recommendations emphasising the need for 
healthcare worker supported testing in those aged 18 
and under.
Effective biomedical innovations such as PrEP have 
the potential to be gamechangers in the HIV epidemic 
in South Africa as part of the combination HIV preven-
tion strategy and have thus been recommended for key 
populations such as sex workers, men who have sex with 
men and adolescent girls and young women aged 15 
to 24 by the NDoH in South Africa.25 However, their 
effectiveness will depend on HIV testing uptake and 
subsequent linkage to care and prevention.26–28 The key 
findings from systematic reviews of the HIV treatment 
cascade suggest that: (1) community- based delivery 
models, including adherence clubs, community health 
workers delivering de- centralised care and task- shifting 
to lay caregivers providing support across conditions, 
improve both ART uptake and sustained retention in 
low- and middle- income settings29–31; (2) peer support 
is effective to deliver health intervention particularly 
to hard- to- reach groups.32 33 Moreover, there is some 
evidence to suggest that HIVST can improve linkage 
to treatment when coupled with community based 
support.19 34 However, there is limited evidence of the 
effectiveness of HIVST to link people who are negative 
to prevention, and in particular PrEP, with or without 
community- based support.
Here, we describe a cluster randomised controlled 
trial to address this critical gap in HIVST evidence and 
linkage for young women aged 18 to 24 years. Although 
all young people aged 18 to 30 years are included in the 
peer- led community based promotion of HIV testing 
and linkage to HIV prevention and care, the aim of this 
trial is to determine whether HIVST delivered by peers 
either directly or through incentivised peer- networks, can 
increase the uptake of ART and PrEP among adolescent 
girls and young women (18 to 24 years) in a high HIV 
transmission setting in KwaZulu- Natal, South Africa. To 
the best of our knowledge, this is one of the first trials 
to test the effectiveness of oral- based HIVST to improve 
uptake of prevention in South Africa.
StuDy AIMS AnD objECtIvES
The specific aims of this trial are to: (1) increase the 
knowledge of HIV status among young women aged 18 
to 24 years old and their young male partners through 
the distribution of HIVST through incentivised peer 
networks or direct distribution by peer navigators 
compared with peer navigators referring them into HIV 
testing services; (2) determine an increase in the rate of 
linkage among young women aged 18 to 24 years to HIV 
prevention and treatment services facilitated by distri-
bution of HIVST through incentivised peer networks 
or direct distribution by peer navigators compared with 
peer navigators referring into services; (3) determine 
an overall increase in young men and women aged 
18 to 30 aware of their status and linked to HIV care 
and prevention; (4) conduct a process evaluation of 
the acceptability, feasibility and reach (out of school, 
recently migrant and living in remote areas) in linking 
18- to 24- year- old women to HIV prevention and treat-
ment services of HIVST distribution through incen-
tivised peer networks, or direct distribution by peer 
navigators or peer navigators referring into services 
and (5) measure the cost per 18- to 24- year- old woman 
linked to prevention and care through peer- led incen-
tivised HIVST delivery system or direct distribution of 
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Figure 1 Map of study sites in Hlabisa subdistrict in 
KwaZulu- Natal, South Africa.
HIVST by peer navigators, compared with peer navi-
gator referring them to services.
MEthoDS/DESIgn
This is a three- arm cluster randomised controlled trial (two 
intervention arms and one control arm) launched in mid- 
March 2019 and currently being carried out by 24 pairs of 
peer navigators that have been randomly assigned to one 
of three arms. The following subheadings grapple with the 
methods, outcomes, procedures and study design among 
others.
Study setting and population
This study will be conducted in Africa Health Research 
Institute’s (AHRI) longstanding demographic surveil-
lance area in northern KwaZulu- Natal. The study area 
is mostly rural, and poor compared with other parts of 
South Africa, with high levels of unemployment (over 
85% of young adults aged 20 to 24 years are unemployed) 
and the local language is isiZulu.8 In the study area, 8 out 
of 100 women aged between 20 and 24 years acquire HIV 
in 1 year, and 4 out of 10 women attending antenatal 
clinics are found to be infected with HIV. Data between 
2011 and 2015 in the study area suggests that sexually 
active women aged 16 to 29 and young adult men have an 
HIV incidence above the threshold of eligibility for PrEP.
The demographic surveillance area provides over 16 
years of household history, and over a million person- 
years of follow- up through annual individual- level 
surveys, which capture sexual behaviour and partner-
ships, reproductive histories and contraception use, 
access to HIV testing and care, access to HIV prevention 
services (including VMMC), as well as socio- demographic 
information. Moreover, through a Memorandum of 
Understanding with the Department of Health, AHRI has 
also embedded data collection clerks within the public 
health clinics to capture electronically any clinical atten-
dance and linking it with the surveillance platform on all 
consenting attendees. This allows us to measure linkage of 
individuals to HIV care and use of contraceptive services. 
As part of a US National Institute of Health (NIH) R01 we 
have selected, trained and employed 24 pairs of peer navi-
gators, working in 24 discrete areas (based on administra-
tive divisions) of the demographic surveillance area (the 
Hlabisa district of uMkhanyakude district of northern 
KwaZulu- Natal, South Africa) to deliver HIV and sexual 
health related promotion to an estimated 12 000 youth 
(male and female) aged 18 to 30 years (~500 per each of 
the 24 administrative areas) and young women aged 18 
to 24 years residing in the administrative areas (figure 1).
theory of change
The intervention that is being tested in this cluster 
randomised controlled trial (cRCT) is guided by a theory 
of change developed through mental models and deduc-
tive development35 entrenched in ecological approach.36 
We theorised that the distribution of HIVST kits (including 
linkage information and referral slips) via peer naviga-
tors or peer social networks (respondent driven sampling 
- RDS) would lead to improved HIV prevention cascade, 
HIV testing uptake and linkage to HIV treatment or preven-
tion services such as PrEP, among young women aged 18 
to 24 years by creating peer- led demand, supporting young 
people to explore their candidacy for HIV care and preven-
tion in privacy, and using social networks to reach those 
who need it most.37 Work done by our group suggested that 
various factors associated with ‘ecological framework’ such 
as the fear of HIV- related stigma of attending a clinic for 
HIV testing and discrimination from healthcare providers 
or community may be addressed by HIVST since individ-
uals can test privately anywhere without fear of being seen 
or judged.2 38 Furthermore, formative work from our group 
suggested that community based delivery of services through 
youth friendly and accessible clinics for the study partici-
pants (walk- ins and those who present the study referral 
slips) could provide confirmatory HIV testing, treatment, 
prevention, contraceptives and other health services.39 40 
Following this, we developed a peer- to- peer intervention to 
reduce the burden of HIV among young women. We used 
the Standard Protocol Items: Recommendations for Inter-
ventional Trials reporting guidelines in this article.41
trial design
This cRCT is comparing two models of peer delivery of 
HIVST in the study sites through incentivised respondent 
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Figure 2 Flow diagram of trial enrolment, randomisation and intervention arms. AGYW, adolescent girls and young women; 
ART,antiretroviral; HIVST, HIV self- testing; PNs, peer navigators; PrEP, pre- exposureprophylaxis.
driven peer networks and direct distribution by peer navi-
gators compared with standard of care (referral to HIV 
testing, prevention and care services by peer navigators) 
in improving the uptake of HIV testing, prevention and 
care among young women (18 to 24 years). Eight pairs of 
peer navigators were randomised and assigned to each 
study arm with the intention of reaching young women 
aged 18 to 24 years with HIVST packs (including referral 
slips) and/or linkage information (including PrEP, 
contraceptives, ART etc) during the 6 month of commu-
nity outreach. Peer navigators are randomised to one of 
three arms: 1) incentivised- peer- networks: peer- navigators 
recruited participants ‘seeds’ to distribute up to five 
HIVST packs (including incentivised coupons) and HIV 
prevention information to peers within social networks. 
Seeds receive an incentive (20 Rand = US$1.5) for each 
respondent who contacts a peer- navigator for additional 
HIVST packs to distribute; (2) peer- navigator- distribution: 
peer- navigators distribute HIVST packs and informa-
tion directly to young people; (3) standard of care: peer- 
navigators distribute referral slips and information. All 
arms promote sexual health and HIV care and prevention 
(including PrEP and ART) and provide barcoded clinical 
referral slips to facilitate linkage to HIV testing, preven-
tion and care services (figure 2).
The unit of randomisation is the pair of peer navi-
gators working in each of the 24 areas included in the 
study. The areas are not adjoining, and each is bordered 
by a natural boundary (eg, roads or streams) or by a 
sizeable distance. Although contamination is inevitable 
in this type of cRCT, the spillover effects are contained 
by measuring the outcome by exposure to the peer- 
navigator cluster in multiple ways, including barcoded 
and colour coded referral slips as well as peer- navigator 
and ward names that determine participant exposure to 
specific intervention components. Coupled with this, we 
are conducting a mixed method process evaluation that 
provides context and add nuance to our understanding 
of any contamination.
outcomes
The long- term goal of the intervention is to increase 
knowledge of HIV status and improve linkage to HIV care 
or prevention services such as PrEP among young women 
aged 18 to 24 years. A number of primary and secondary 
measures have been defined a priori. An interim analysis 
of the primary outcome will be conducted at 3 months.
Primary outcome
The primary outcome compares the difference in linkage 
rate between arms, defined as the number of women 
(18 to 24 years) per peer- navigator month of outreach 
work (/pnm) who linked to clinic- based PrEP eligibility 
screening or started ART, based on HIV- status, within 90 
days of referral.
Secondary outcomes
The following calculations are planned for the secondary 
outcomes:
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Figure 3 Peer navigators community outreach workflow. GPS, Global Positioning System; PrEP, pre- exposureprophylaxis; 
REDCap,Research Electronic Data Capture; VMMC, voluntary medical male circumcision.
 ► Comparison of the difference per study arm of the 
total number of linkages (AGYW aged 18 to 24) per 
100 clinic referral slips distributed.
 ► Comparison of the difference per study arm of the 
total number of linkages in men and women aged 18 
to 30 per peer navigator outreach month.
 ► The change in proportion of young people aged 18 to 
24 years who are aware of HIVST and who have used 
HIVST over time.
 ► Comparison of the difference per study area in the 
proportion of 18- to 24- year- olds who report knowl-
edge of HIV status and uptake of ART, PrEP and 
VMMC in the surveillance area.
 ► The proportion of hard- to- reach adolescent girls and 
young women (aged 18 to 24 years) linked to care in 
the three study arms.
Description of study arms
Intervention arm 1 - incentivised network distribution 
of HIVST: n=8 pairs of peer navigators are using RDS 
approach to distribute HIVST with health promotion and 
linkage information (eg, clinical referral slips and infor-
mation about HIV and PrEP). Each pair of peer navigator 
recruits n=10, 18 to 24 years old female seeds from the 
participating communities. Each seed fills a brief service 
recipient questionnaire — self- filled on a tablet. Following 
which they receive verbal health promotion from the 
peer- navigator on the HIV prevention services available, 
the importance of sexual health, the benefits of HIV testing 
PrEP and ART and a demonstration of HIVST. Seeds are 
asked to recruit AGYW aged 18 to 24 years preferentially 
but not exclusively and to avoid distribution of HIVST to 
those under the age of 18 or over the age of 30. All seeds 
are asked to complete a brief check of their understanding 
of the information provided to them, particularly informa-
tion about not using HIVST if someone is on ART, the 
window period, the recommended support to those under 
18 using HIVST, and the need for confirmatory testing.
As shown in figure 3, individuals who return with one 
of the coupons to a peer navigator undergo the same 
procedure as the seeds as described above. They are also 
given up to five uniquely numbered incentivised recruit-
ment coupons and HIVST kits to pass on. When coupons 
are returned, the original individual who handed out 
the coupon receives a sum of R20 (US$1.5) in airtime 
per friend or peer who returns the coupon. This sum 
is a reimbursement for the time that they have spent in 
explaining and demonstrating the use of an HIVST and 
is not seen to be an undue incentive to coerce members 
of their social network to participate. There is no gender 
restriction of those recruited through the networks, 
however the primary outcome will be measured in young 
women aged 18 to 24 years only.
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Table 1 Inclusion and exclusion criteria for receiving the 
intervention, that is, the recruitment by peer navigators and/
or seeds to receive HIVself- testing packs or clinical referral 
slips
Inclusion criteria Exclusion criteria
Participant must not be older than 
30 years and younger than 18 
years
Participants under 18 
years or older than 30 
years
Participant must agree to 
participate
Participant unwilling to 
participate
Both males and females can be 
included
None
Must not be known to be on ART – 
based on self- report
If on ART
ART, antiretroviral.
Table 2 Inclusion and exclusion criteria for ascertaining the 
primary outcome
Inclusion criteria Exclusion criteria
Participant must not be 
older than 24 years and 
younger than 18 years
Participants under 18 years or 
older than 24 years
Provide written informed 
consent
Participants not willing to 
consent or unable to provide 
informed consent
Females Males
Must not be known to be 
currently on ART
Currently on ART
ART, antiretroviral.
Intervention arm 2 - peer navigator direct distribution 
of HIVST: n=8 pairs of peer navigators are distributing 
HIVST packs with health promotion and linkage informa-
tion (eg, clinical referral slips and information about HIV 
and PrEP) directly to young people aged 18 to 30 years 
over a period of 6 months. Each person contacted fills a 
brief service recipient questionnaire — self- filled on a tablet. 
Following which they receive verbal health promotion 
from the peer- navigator on the HIV prevention services 
available, the importance of sexual health, the benefits 
of HIV testing, PrEP and ART and a demonstration of 
HIV self- screening. All participants are asked to complete 
a brief check of their understanding of the information 
provided to them, particularly information about the 
unreliability of HIVST if someone is on ART, the window 
period, the recommended support to those under 18 
using HIVST and the need for confirmatory testing.
Control arm 3: n=8 pairs of peer navigators are currently 
distributing packs with health promotion and linkage 
information (eg, clinical referral slips and information 
about HIV and PrEP) to encourage young people aged 18 
to 30 years to test for HIV at clinics, and link to services/
care. Each female aged 18 to 30 approached fills a brief 
service recipient questionnaire — self- filled on a tablet. 
Following which they receive verbal health promotion 
from the peer- navigator on the HIV prevention services 
available, the importance of sexual health, the benefits of 
HIV testing PrEP and ART.
Study oversight
An independent scientific Technical Advisory Group 
(TAG) was formed by the Unitaid- funded HIV Self- Testing 
Africa initiative (STAR — a consortium of scientists 
conducting HIV self- testing related research in different 
countries) to monitor and supervise the progress of data 
collection, provide independent review of data collected 
during all cRCTs conducted under the STAR initiative, 
and assist investigators in disseminating results. TAG 
comprises members with expertise in HIV epidemiology, 
statistics, health economics, social science and AGYW. 
TAG will convene periodic meetings to review data and 
discuss any issues emanating from this trial.
Study inclusion and exclusion criteria
Complete inclusion and exclusion criteria are summarised 
in tables 1–3. There are criteria for different recruitment 
stages in the trial. Above all, participants must not be 
less than 18 and not more than 30 years old. They must 
provide informed consent, not currently on ART and 
must be living in the study sites.
Study recruitment and procedures
Study recruitment: Peer navigators are a cadre of recently 
matriculated youth or college graduates aged 18 to 30 
years (male and female) recruited from the research 
community through the local municipal and traditional 
leaders. Between June 2018 to September 2018 partici-
pants underwent a 20 week training programme (3 days a 
week) which covered, youth development, HIV and sexual 
health information, HIV counselling and testing, confi-
dentiality, ethics and research methods, study procedures 
and HIVST. Progress was evaluated using written and oral 
assessments to select 48 peer navigators to work in pairs 
and implement the intervention in their areas. The peer 
navigator intervention mirrors the South African cadre of 
community caregivers.
Before the peer navigators distribute the colour coordi-
nated HIVST packs (each arm has its designated colour 
such as yellow, blue and pink) with unique identifiers in 
the intervention arms 1 and 2 or information packs in 
arm 3, the packs are being scanned and study participants 
are provided with information about the study and fill a 
brief service recipient questionnaire to be completed within 
Research Electronic Data Capture (REDCap - developed 
by Vanderbilt University, USA)42 on a tablet (figure 3). 
Data collected at this point includes the date of recruit-
ment, and the ID of peer navigator who recruited them, 
their age and area of residence. Participant’s name, ID 
(eg, SA national number) and telephone or WhatsApp 
contact are optional. Those who are recruited through 
RDS will also be asked to provide data on their network 
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Figure 4 Mobile/fixed clinics service workflow. ART, antiretroviral;BSID, Bayley Scales of Infant Development; DoH, 
Department of Health; PrEP,pre- exposure prophylaxis; REDCap, Research Electronic Data Capture; SA_ID,South Africa national 
identification number; STI, sexually transmittedinfection.
Table 3 Inclusion and exclusion criteria for ascertaining the 
secondary outcome
Inclusion criteria Exclusion criteria
Participant must not be 
older than 30 years and 
younger than 18 years
Participants under 18 years or 
older than 30 years
Provide written informed 
consent
Participants not willing to 
consent or unable to provide 
informed consent
Must not be known to be 
currently on ART
Currently on ART
ART, antiretroviral.
size, barcode of the RDS coupons and the additional 
HIVST kits are scanned for further distribution.
Peer navigators spend ~30 min with each willing partici-
pant to explain the benefits of linking to care and preven-
tion. Those explaining HIVST need 15 to 20 min extra 
and some young people require more time or more 
visits. This data is captured in REDCap for the purpose 
of process evaluation and costing. This data will be used 
in an aggregate way to understand the process and cost of 
the service delivery. Individualised data from the survey 
will only be used in those participants that consent to 
their clinical data being linked and used for research 
purposes. If a participant withdraws their consent at any 
time, their data will be deleted from the research data set.
Study enrolment: Both walk- ins and study participants 
aged 18 to 30 years are eligible for receiving services from 
the designated study clinics. However, only those who 
have been referred through one of the three arms are 
eligible for study enrolment. This is being conducted 
by trained clinical research assistants in the designated 
study mobile and fixed clinics (figure 4). Also, all young 
women aged 18 to 24 years coming to one of the 11 
primary healthcare clinics (PHC) or the mobile clinics 
in the surveillance sites are being directed by our AHRI 
data collection clerks to our research nurses. In both 
settings, the clinical research assistants or the research 
nurses explain the study and screen the young person 
for eligibility using a brief eligibility screening question-
naire on REDCap on a tablet. This includes questions to 
ascertain eligibility as well as arm of the study. If available, 
the clinical referral slip with the barcode with the unique 
identifier is scanned. The brief screening questionnaire 
that has further simple questions to ascertain if they were 
referred through any of the arms, that is, receiving any 
of the three colour coded packs/referral slips, or contact 
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with a named peer navigator, or referral through peer 
network. Interested eligible participants then go through 
the process of informed consent. Participants provide 
written informed consent for enrolment into the study 
and specifically to use the information on their linkage to 
care as an outcome and to link their baseline questions.
Clinical procedures: Irrespective of whether they 
consent to the study, all eligible individuals attending 
clinics are offered confirmatory HIV testing, with two 
point of care tests and then blood sent to laboratories for 
ELISA testing (Genscreen ULTRA HIV Ag- Ab qualitative 
immunoassay (fourth Generation) Bio- Rad, Marnes- la- 
Coquette, France). Individuals who test HIV- negative 
receive counselling around the benefits of PrEP and HIV- 
positive individuals receive counselling around the bene-
fits of immediate starting of ART. If they agree, they will 
undergo clinical screening for PrEP and ART. Screening 
includes Point of Care tests for creatinine (StatSensor- I 
create- test strips, Nova Biomedical UK) to assess renal 
function and hepatitis B (Alere Determine HBsAg, Alere 
International Limited, Ballybrit, Galway, Ireland; Archi-
tect i2000 analyzer, Abbott Diagnostics, Abbott Park, Illi-
nois, USA), with vaccination offered to those who are 
negative, and sexual behaviour questionnaire to assess 
eligibility.
If HIV positive, ART is started by the professional nurses 
in any of 11 PHCs in the study sites. Patients who are 
eligible for PrEP are started in the three PrEP providing 
clinics (the mobile vans or the fixed urban adolescent 
and youth friendly clinic). Persons who are not eligible 
for PrEP receive counselling and, as indicated, a clinic 
referral with the screening results. A professional nurse 
initiates PrEP or ART usually on the same day or within 
2 weeks of the screening visit. The professional nurse 
provides PrEP counselling that includes (1) sexual health 
promotion, with an emphasis on tackling the multiple 
health- related behaviours that will affect fertility and 
sexual pleasure (sexually transmitted infections, mental 
health, alcohol, diet and exercise); (2) assessment of 
fertility desire and contraception counselling; (3) choice 
of contraception and condoms; (4) HIV- negative men 
are also counselled around the benefits of VMMC and 
referred accordingly.
The counsellors provide counselling on adherence and 
develop an individualised adherence plan with the offer 
of face- to- face or virtual (WhatsApp/text based) adher-
ence support. If the participant agrees to immediate PrEP 
initiation, s/he is issued with a month’s supply of generic 
tenofovir disoproxil fumarate and emtricitabine. Baseline 
and follow- up bloods are taken and processed as per SA 
National Department of Health guidelines. The profes-
sional nurse registers the participant at the clinic (or 
updates the record if the participant is already registered) 
so that the participant’s records are available should the 
participant seeks care there. Participants receive a phone 
call 7 days after initiating PrEP to complete a standard 
symptom screen for adverse effects and be referred 
to clinic for care if necessary. Participants have a clinic 
appointment scheduled 1 month, after PrEP initiation, 
as per national guidelines; appointments for refills and 
monitoring will be quarterly thereafter through either 
the mobile clinic, or other community- based refill points. 
Neutral text message reminders are provided for partic-
ipants who have access to private messaging and phone 
calls. Participants are able to reschedule their appoint-
ments by text message, WhatsApp or calling the clinical 
hotline. Contact information is provided for the clinics 
whom participants can contact at any time.
randomisation
We defined cluster as a pair of peer navigator (PN) who 
live and work in one of the 24 administrative areas that 
were included in the trial. Peer navigators were preas-
signed to 24 areas before the randomisation process. 
Using data from our recent Determined, Resilient, 
Empowered, AIDS- free, Mentored and Safe (DREAMS, 
combination HIV prevention) Impact Evaluation study 
which collected data from a representative sample of 
young women residing in the study areas, a restricted 
randomisation was applied to get balanced covariates 
(location, HIV testing prevalence and uptake of DREAMS 
combination HIV prevention by adolescent girls and 
young women) across the three arms. We generated a 
random set of possible 100 000 allocation options. After 
applying all three restrictions, a total of 47 924 possible 
allocations remained, and a random number was gener-
ated and assigned to each allocation option. The random 
numbers were ranked from lowest to highest and the 
allocation option with the first rank was then selected. A 
randomisation list with intervention arms named alpha-
betically (A, B and C) was generated.
Following the statistical randomisation, a public rando-
misation was conducted where peer navigators were 
divided into three groups (A, B and C). Each group had 16 
allocated PNs and three floating ones. Each group chose a 
suitable name and a leader who represented them. Group 
leads picked a concealed number to determine the order 
of picking their study arm from a box. The facilitator 
shook the box so to make sure that each concealed arm 
in the box had an equal chance of being picked. Lastly, 
the leaders were asked to open and announce the arms of 
their respective groups to the bigger group.
blinding
The statistician and clinical staff did not participate in the 
public randomisation with peer navigators and they will 
remain blinded until the results of the study have been 
finalised.
Sample size calculations
Based on 2017 data, we estimated ~500 age eligible 18 
to 30 year olds live in each peer navigator team catch-
ment area, of whom we anticipated at least 200, 18- to 
24- year- old females will be handed a study pack (so cluster 
size at least 200). We estimated this based on two peer navi-
gators working approximately 1000 hours over the study 
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period per cluster. We estimated that they would reach 
two young adults per each 4 hour of work and at least one 
would accept a study pack. We calculated the sample size 
calculation using the primary outcome, the rate of linkage 
after 90 days among women ages 18 to 24 years. Using our 
existing data on uptake of HIV testing in the DREAMS 
interventions as well as our data on uptake of testing and 
linkage to HIV care in the demographic surveillance 
rounds of, we estimated that one woman would link per 6 
months of peer navigators outreach work time in the stan-
dard of care. With eight peer educator pairs (or clusters) 
per arm and a cluster coefficient of variation (k) of 0.25, 
we will have 80% power to detect a 100% increase in rate 
from 1 woman to 2 women per 6 months of follow- up, 
and 90% power to detect a 150% increase from 1 woman 
to 2.5 women per 6 months of follow- up. We have chosen 
policy and clinically relevant increases in linkage to care. 
Assuming additional clustering of the outcome within 
peer educators and increasing the coefficient of variation 
(k) to 0.35, we have 80% power to detect a 150% increase 
in rate from 1 woman to 2.5 women per 6 months of 
follow- up. All sample size calculations assume two- tailed 
statistical tests with alpha=0.05.
Process evaluation
Our aim is to assess the acceptability, feasibility and 
fidelity of the peer delivery model in each arm in facili-
tating linkage to care. We compare the pattern of recruit-
ment per arm and assess the proportion of hard- to- reach 
AGYW (aged 18 to 24 years) — defined as out of school, 
recently migrated and those who live in remote areas 
linked to care in the three study arms. We will also explore 
potential unintended consequences and ethical issues 
that arise during peer referral and HIVST and ascertain 
what works for whom and when to be able to modify the 
intervention to improve equitable reach and coverage. 
Specifically, we will explore the reach of network recruit-
ment compared with peer outreach work, in terms of 
reaching more vulnerable groups (out of school, recently 
migrated and those who live more remotely). Entrenched 
in realist evaluation, this process evaluation uses a mixed 
method approach (quantitative and qualitative research 
techniques) to investigate implementation, mechanisms 
of impact and contextual factors, informed by the UK 
medical research council guide43 and wider implementa-
tion science literature with a focus on fidelity, reach and 
acceptability.44
Cost-effectiveness evaluation
We compare the costs in intervention and control arms. 
Cost per case linked to PrEP eligibility assessment (HIV- 
negative) and cost per case started on ART (HIV- positive). 
To establish costs, we are using both a bottom- up 
ingredient- based costing approach and a top- down 
costing approach using the study budgets and expendi-
ture reports. Specifically, we calculate and cost the actual 
time spent by peer- navigators in each arm for each person 
linked to care and prevention.
Data collection
Participant survey and clinic linkage
A short survey (service recipient questionnaire) is admin-
istered to consenting individuals participating in the 
study. The questionnaire collects data on participant’s 
demographic information and coupon identification. The 
data is captured on REDCap on a tablet. The survey takes 
approximately 5 min to complete and is administered in 
both English and isiZulu. The primary outcome of linkage 
is measured through identifying the consenting eligible 
young women who link to care through the 11 PHCs and 
the mobile clinics. We use an algorithm to identify which 
arm the individual came from, including the barcode on 
the referral slip they bring, the colour of the referral slips 
or HIVST pack, their area of residence and the identity of 
the peer- navigator that recruited them.
Programmatic data
In addition to the survey, we collect the programme data 
records from the peer navigators daily reporting of their 
outreach activities. This includes the number of young 
people they have counselled and the numbers they have 
referred to services and the brief service recipient data 
they have collected on those who have received referral 
slips or HIVST packs. We use the programme data in an 
aggregate way (disaggregated only by gender) to under-
stand the reach and coverage of the programme and 
compare that with those who link to care. We also use 
data on changes in self- reported HIVST and linkage 
services collected through the population intervention 
surveillance platform.
Participant in-depth interviews
In- depth interviews (IDIs) are being conducted with the 
peer navigators (n=30), clinical team (n=6) stationed in 
clinics in the participating communities and a purposive 
sample of young women aged 18 to 24 years (including 
young men n=45; 30 females (10 per arm), 15 males (five 
per arm)) across the three arms and clinics. The inter-
views are conducted by trained social scientists fluent in 
English and isiZulu and take approximately 60 min in 
length depending on the participant’s responses, and 
this enables the researchers to understand, contextualise 
and explore participants perceptions of the study and 
some of the issues emanating from the trial. The small 
number of IDI participants in qualitative study is allowed 
since deeper meanings of concepts and thematic areas 
are explored. To limit disturbances and ensure privacy, 
the IDIs are conducted in a private space suitable for 
the participant, and audio recorded with interviewees’ 
consents. Prior to the interview, participants are encour-
aged to use pseudo names instead of their real names.
Statistical analysis
The analysis of primary outcome follows an intention- to- 
treat (ITT) and per- protocol approaches. The analysis 
of secondary outcomes will be undertaken using per- 
protocol approach only. The primary outcome compares 
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the difference between the rate of linkage of 18- to 
24- year- old women to HIV confirmatory HIV testing, ART 
(if HIV- positive) or PrEP counselling (if HIV- negative). 
The rate is defined as the number of linkages per month 
of peer navigator outreach activities. The numerator is 
defined as the number of young women aged 18 to 24 who 
attend clinic for confirmatory HIV testing, PrEP counsel-
ling or ART, following HIVST distribution or peer navi-
gator referral to HIV testing, treatment and prevention 
services. The denominator for ITT analysis is the entire 
time (study duration) spent by peer navigators doing 
their peer outreach work. For the on- treatment analysis, 
we will use the actual time spent by peer navigators on 
distributing packs in each arm. The time worked by each 
peer navigator will be combined to get the total time per 
pair of peer navigator. The difference in rate of linkage 
between the study arms will be calculated — incentivised 
HIVST delivery through peer network and direct distri-
bution of HIVST will be compared with standard of care.
Since we randomised the pairs of peer navigator (clus-
ters), the rate of linkage will be calculated for each pair of 
peer navigator using aggregate data for each cluster. Since 
the number of clusters are small, the effect of the interven-
tion will be estimated using a two- stage approach based 
on cluster- level summaries.45 The cluster- level approach, 
although less statistically efficient than methods based 
on individual level regression, is more robust when there 
are a relatively small number of clusters. All analyses will 
be performed using Stata V.15 (StataCorp LP, College 
Station, Texas, USA).
Cluster- level linkage rates will be calculated and used 
to estimate the unadjusted rate ratio and its 95% CI for 
the effect of each intervention arm compared with the 
standard of care; the mean difference in linkage rates 
between each arm and standard of care, and against each- 
other will be assessed using a t- test. A rate ratio adjusting 
for substantial covariate imbalance at baseline will also be 
calculated, using a two- stage process; all covariates will be 
prespecified in the analysis plan. To identify covariates 
for adjustment, baseline characteristics of each arm will 
be presented, and the size of the difference of covariates 
known to be associated with the outcome will be assessed 
quantitatively.
As part of the exploratory analysis, we will perform a (i) 
subgroup analysis by gender and area and (ii) two inter-
vention arms will be compared with one another (incen-
tivised HIVST delivery through peer network approach 
will also be compared with direct distribution of HIVST 
approach). To expand on this, the data from the client 
survey captured on REDCap dashboard will be exported 
into Stata, cleaned and analysed. All reporting will 
conform to Consolidated Standards of Reporting Trials 
guidance for cluster randomised trials.44 45
Qualitative analysis
NVivo software will be used for categorisation and coding 
of emerging themes from the interview transcripts. 
Identified themes (including participants’ quotes) and 
interview transcripts will be reviewed and compared 
by the research team for inconsistencies and adequate 
representation of participants’ views. Emerging themes 
that address the key focus of the study will be examined 
and analysed following an interpretivist approach.46
Adverse events reporting
HIV testing, including HIVST, is well established and 
known to have a high level of safety. However, harmful 
reactions can occur. Adverse events (AE) related to 
HIVST include all undesirable experiences that result 
directly from use of the HIVST kit itself or as a reaction 
from others due to the presence of the kit, use of the 
kit or results produced from the kit. AEs can be from 
one person to another, or a person to themselves, and 
can occur before, during or after self- testing. We rely 
on participants to report any AEs to the study staff or 
through the hotline provided on the referral slip. Also, 
during PrEP resupply and monitoring visits, participants 
complete a standardised symptom screening question-
naire for adverse effects of PrEP as per South African clin-
ical guidelines. Furthermore, all participants will receive 
regular creatinine tests to monitor their renal function. 
Participants who have severe (grade 3/4) adverse effects 
and serious adverse effects, are referred to the study clini-
cian for medical evaluation. All participants who experi-
ence adverse events receive follow- up until the adverse 
event is resolved.
AEs and serious adverse events (SAEs) are captured 
through the process evaluation and community engage-
ment units and the telephone hotline. In addition, peer 
navigators and clinic staff log AEs using our incident 
reporting form for up to 12 months after the start of the 
intervention. Reported AEs and SAEs are monitored, 
categorised based on an established grading system. SAEs 
are logged, with the Principal Investigator to evaluate 
the SAE for seriousness and likely relationship to the 
intervention. Related SAEs are reported to University of 
KwaZulu- Natal (UKZN) and London School of Hygiene 
and Tropical Medicine (LSHTM) Ethics Review Boards. 
All SAEs are reported regularly through 6 month prog-
ress reports to TAG members, local and international 
collaborators. Annual reports with full listings of SAEs will 
be submitted to Ethics Review Boards.
Data management
Quantitative data are collected directly on the study tablet 
via REDCap database and resides within a single MySQL 
database server within a secure server cluster. Study- 
specific electronic laboratory results are transferred 
directly to a secured server for storage. Qualitative data are 
stored in the form of Word files or in Excel both of which 
can be uploaded into NVivo qualitative data manage-
ment programme. The use of MS Word will ensure that 
data can in future be shared for use in different analysis 
programmes. These files will be kept on a secure access- 
controlled folder on a secured server. Qualitative audio 
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files will be destroyed once they have been transcribed, 
translated and quality controlled.
Patient and public involvement
Although we did not involve patients or the public in 
the design of the study, findings from previous studies 
conducted within the community were useful during the 
study design phase. The study was also presented to the 
community advisory board and the district department of 
health for comments before it was submitted to Institu-
tional Review Boards for ethics approval. The results of 
the study will be shared with the peer navigators and the 
research community through community dialogues and 
the community advisory board.
EthICS AnD DISSEMInAtIon
Ethical consideration: confidentiality and informed consent
All staff (including peer navigators) have been provided 
with training on research ethics such as confidentiality, 
voluntary participation and good clinical practices. 
Anonymity and confidentiality are ensured at all levels of 
the research process, and none of our reports, presen-
tations or articles will contain study participants identi-
fying information. Pseudonyms are used when reporting 
the data particularly qualitative data. Each participant is 
assigned a unique non- identifying participant identifi-
cation number. Prior to their involvement in the study, 
participants are provided with adequate information 
about the study and are allowed to ask questions for clar-
ifications. Voluntary informed consent is collected only 
if participants have the full understanding of the study 
procedures. A copy of the signed consent form is given 
to them. Participants are informed about the impor-
tance of the confirmatory diagnostic testing. An anon-
ymous support hotline is provided on the referral slips 
should they need to discuss their HIV status, counselling 
and further linkage to HIV care or other health services. 
All participant irrespective of their consent to partic-
ipating in the study are eligible for the clinical services 
provided through the study. The study was approved by 
and conforms to the ethical guidelines and standards of 
UKZN, LSHTM and WHO.
Dissemination plan
The results of this study will be disseminated through 
traditional academic channels (peer- reviewed journal 
publications) as well as on different information dissem-
ination platforms such as conferences, workshops, 
community meetings and symposia. The results of the 
study will also be presented at Self- Testing Africa (STAR) 
consortium meetings and will be included in the WHO 
guidelines. The results of the study will be shared with 
the peer navigators and the research community through 
community dialogues and the AHRI community advisory 
board. A detailed findings report will be shared with the 
Department of Health and other stakeholders to inform 
policy.
DISCuSSIon
Despite the burden of HIV and the availability of free HIV 
testing and treatment in our local PHCs, HIV status knowl-
edge remains low among young people <30 years2. Several 
complex barriers (eg, stigma, confidentiality, family rejec-
tion, waiting times and lack of youth friendly services etc) 
impeding on young people’s access to HIV care services 
were identified in a formative research we completed in 
2018.2 38 Studies including systematic reviews13 19 have 
shown HIVST to be a promising alternative HIV testing 
option because it is private, flexible and an efficient 
method. However, there is limited evidence on the use 
of HIVST to improve linkage to prevention such as PrEP. 
The overarching goal of this trial is to address the gap in 
HIV testing and linkage to HIV prevention among young 
women aged 18 to 24 years. This goal will be achieved 
through the assessment of two HIVST delivery models 
(incentivised peer network vs direct distribution by peer 
navigators) compared with the standard of care of peer 
navigator only.
A major strength of this study is the development of 
a theoretically derived intervention that can be imple-
mented through existing cadre of community caregivers 
and peer- to- peer networks across sub- Saharan Africa.47–50 
If found to be effective in increasing HIV testing uptake 
and prevention, the intervention is designed to be rolled 
out. Also, using a rigorous cost- effectiveness analysis will 
allow South African policymakers to evaluate the cost- 
benefit ratio of using the different models of distribution 
in different settings. Furthermore, by collecting rigorous 
data on linkage to prevention both through the trial and 
from our surveillance infrastructure, we can understand 
the potential population impact of the different methods 
of HIVST distribution on knowledge of status and linkage 
to care and prevention. Ultimately this will provide 
evidence of the potential of the intervention to attract 
young people into the HIV care and prevention cascade 
and inform the evidence base to reduce the mortality and 
morbidity in youth. Lastly, rigorous process evaluation 
and collection of data on all adverse events and social 
harms will provide important data around some of the 
concerns about HIVST, that is, the potential for coercive 
test, depression, anxiety, suicidality or intimate partner 
violence.
In order to reduce the risk of contamination due to 
the proximity of the areas and the nature of the inter-
vention, we have piloted several methods including 
the use of referral slips with unique codes and colour 
coordinated packs to identify the arm individuals come 
from when they link to care. Previous data from nested 
cohorts that we have followed up in our area has shown 
that young people rarely migrate within our surveillance 
area given that only 220 of 2184 young people <25 years 
cohorts moved from one cluster to another in 2017/2018. 
Furthermore, the process evaluation will help us under-
stand the delivery model in each arm as well as unin-
tended consequences and ethical issues that arise during 
the study and ascertain what works for whom and when to 
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be able to modify the intervention to improve equitable 
reach and coverage.
In conclusion, the results of this trial are expected 
to contribute to WHO guidelines and informed policy 
aimed at implementation and scale- up of HIVST and 
PrEP in South Africa. Also, this study will address crit-
ical gaps in the literature on HIV testing and prevention 
interventions for young people particularly females aged 
18 to 24 years in Southern Africa.
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